Richard E. Pratley, MD

Richard E. Pratley, MD

Medical Director at the AdventHealth Diabetes Institute, Senior Investigator, Diabetes Program Lead at the Translational Research Institute

Translational Research, Infectious Disease

Pratley

Overview

Richard Pratley, MD, is a board-certified internal medicine physician and nationally recognized diabetes expert with advanced training in gerontology, geriatrics and clinical physiology and metabolism. He sees patients at AdventHealth Medical Group’s diabetes and endocrine specialty practice in Orlando and The Villages while also serving as the Medical Director of the AdventHealth Diabetes Institute and as a senior scientist in diabetes research for AdventHealth. He is a leading authority on new and emerging treatments for diabetes and its comorbidities, which is why many area physicians refer their patients to him for advanced diabetes care. Dr. Pratley earned his medical degree at Wayne State University in Detroit and undertook his residency at the University of Michigan. He next completed three consecutive fellowships in clinical physiology and metabolism, gerontology and geriatrics, and geriatrics at the National Institute on Aging in Baltimore, Johns Hopkins University and the University of Michigan, respectively.

Articles

Indirect treatment comparisons: Choosing the right tool for the job.

Diabetes, obesity & metabolism

2022

Y Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

2022

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

BMJ OPEN DIABETES RESEARCH & CARE

2022

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.

Circulation

2022

Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 d

Contemporary clinical trials

2022

Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes.

Diabetes, obesity & metabolism

2022

The Ile191Val Variant of the TAS1R2 Subunit of Sweet Taste Receptors Is Associated With Reduced HbA(1c) in a Human Cohort With Variable Levels of Glucose Homeostasis

FRONTIERS IN NUTRITION

2022

Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

2022

Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes

Diabetes technology & therapeutics

2022

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV

DIABETES OBESITY & METABOLISM

2022

More Publication Information

Education & Training

Education

Wayne State University School of Medicine; University of Michigan- Ann Arbor; John Hopkins School of Medicine; University of Michigan - Dearborn

Residency

University of Michigan, Ann Arbor, MI

Fellowship

University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT01843127

GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide Active-control Period

Icon for trial | GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Ex

The primary purpose of this study is to understand the reasons why Ranolazine may potentially treat patients with T2DM. Ranolazine has been shown to block glucagon and therefore results in a lowering of blood glucose levels. Th ...

NCT04805970

RECODE: Researching Covid Outcomes in Diabetes

Icon for trial | RECODE: Researching Covid Outcomes in Diabetes

This study is currently enrolling.

We invite you to take part in a research study because you have previously had a confirmed diagnosis for COVID-19 (the new coronavirus) disease. You have recovered, or are recovering from this disease, with no fever or cough wi ...

NCT04628481

GLADIATOR: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.

Icon for trial | LDX0319 GLADIATOR: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at base

This study is currently enrolling.

The purpose of this study is to check and collect data of how the body absorbs, distributes and gets rid of the study drug in the blood during the first cycle of LDX0319 study treatment. These data will help improve knowledge a ...

NCT05394519

REDEFINE2: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes.

Icon for trial | REDEFINE2: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes.

This study is currently enrolling.

Study Purpose: The purpose of the study is to investigate the efficacy and safety of two medications, cagrilintide and semaglutide. Cagrilintide in combination with semaglutide is currently under development by Novo Nordisk for ...